Which has preferable earnings & valuation, QURE or ANNX?

uniQure has higher revenue and earnings than Annexon. uniQure is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 101.08 -$198.97M -$4.01 N/A Annexon N/A N/A -$206.69M -$1.16 N/A

Is QURE or ANNX more profitable?

Annexon has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Annexon's return on equity of -106.15% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,350.73% -111.96% -29.01% Annexon N/A -106.15% -79.82%

Does the media prefer QURE or ANNX?

In the previous week, uniQure had 28 more articles in the media than Annexon. MarketBeat recorded 36 mentions for uniQure and 8 mentions for Annexon. Annexon's average media sentiment score of 0.83 beat uniQure's score of 0.18 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 5 Very Positive mention(s) 7 Positive mention(s) 18 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ANNX or ZLAB?

Zai Lab has higher revenue and earnings than Annexon. Zai Lab is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.16 N/A Zai Lab $460.16M 6.02 -$175.54M -$1.71 N/A

Is ANNX or ZLAB more profitable?

Annexon has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Zai Lab -41.86% -27.43% -16.72%

Does the media favor ANNX or ZLAB?

In the previous week, Annexon had 5 more articles in the media than Zai Lab. MarketBeat recorded 8 mentions for Annexon and 3 mentions for Zai Lab. Annexon's average media sentiment score of 0.83 beat Zai Lab's score of -0.26 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is ANNX or IMNM more profitable?

Immunome's return on equity of -50.56% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Immunome N/A -50.56% -46.93%

Does the media prefer ANNX or IMNM?

In the previous week, Annexon and Annexon both had 8 articles in the media. Annexon's average media sentiment score of 0.83 beat Immunome's score of 0.64 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 1 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CDNA or ANNX?

CareDx has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CareDx $379.80M 9.15 -$21.35M $2.07 32.44 Annexon N/A N/A -$206.69M -$1.16 N/A

Is CDNA or ANNX more profitable?

CareDx has a net margin of 24.23% compared to Annexon's net margin of 0.00%. CareDx's return on equity of 2.87% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets CareDx 24.23% 2.87% 2.17% Annexon N/A -106.15% -79.82%

Does the media favor CDNA or ANNX?

In the previous week, Annexon had 4 more articles in the media than CareDx. MarketBeat recorded 8 mentions for Annexon and 4 mentions for CareDx. Annexon's average media sentiment score of 0.83 beat CareDx's score of 0.52 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareDx 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ANNX or GMTX?

Annexon presently has a consensus price target of $15.29, suggesting a potential upside of 264.81%. Given Annexon's stronger consensus rating and higher probable upside, research analysts plainly believe Annexon is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 2 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.40 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, ANNX or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.16 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is ANNX or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Gemini Therapeutics N/A -38.78% -35.88%

Annexon (ANNX) Competitors

$4.19 +0.07 (+1.70%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.26 +0.07 (+1.67%)

As of 10/2/2026 07:31 PM Eastern

Compare

ANNX vs. QURE, ZLAB, IMNM, CDNA, and GMTX

Should you buy Annexon stock or one of its competitors? Annexon's main competitors and comparable companies include uniQure (QURE), Zai Lab (ZLAB), Immunome (IMNM), CareDx (CDNA), and Gemini Therapeutics (GMTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Annexon compare to uniQure?

uniQure (NASDAQ:QURE) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

78.8% of uniQure shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 10.3% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

uniQure has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Annexon has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

In the previous week, uniQure had 28 more articles in the media than Annexon. MarketBeat recorded 36 mentions for uniQure and 8 mentions for Annexon. Annexon's average media sentiment score of 0.83 beat uniQure's score of 0.18 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	5 Very Positive mention(s)	7 Positive mention(s)	18 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annexon	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure presently has a consensus target price of $56.64, suggesting a potential upside of 141.42%. Annexon has a consensus target price of $15.29, suggesting a potential upside of 264.81%. Given Annexon's higher possible upside, analysts clearly believe Annexon is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

uniQure has higher revenue and earnings than Annexon. uniQure is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	101.08	-$198.97M	-$4.01	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

Annexon has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Annexon's return on equity of -106.15% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Annexon	N/A	-106.15%	-79.82%

Summary

uniQure and Annexon tied by winning 8 of the 16 factors compared between the two stocks.

How does Annexon compare to Zai Lab?

Annexon (NASDAQ:ANNX) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Zai Lab has higher revenue and earnings than Annexon. Zai Lab is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Zai Lab	$460.16M	6.02	-$175.54M	-$1.71	N/A

Annexon has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Zai Lab	-41.86%	-27.43%	-16.72%

41.7% of Zai Lab shares are held by institutional investors. 10.3% of Annexon shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Annexon presently has a consensus price target of $15.29, indicating a potential upside of 264.81%. Zai Lab has a consensus price target of $37.25, indicating a potential upside of 53.10%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Annexon had 5 more articles in the media than Zai Lab. MarketBeat recorded 8 mentions for Annexon and 3 mentions for Zai Lab. Annexon's average media sentiment score of 0.83 beat Zai Lab's score of -0.26 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Annexon has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Summary

Annexon beats Zai Lab on 9 of the 16 factors compared between the two stocks.

How does Annexon compare to Immunome?

Annexon (NASDAQ:ANNX) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Immunome's return on equity of -50.56% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Immunome	N/A	-50.56%	-46.93%

Annexon presently has a consensus target price of $15.29, suggesting a potential upside of 264.81%. Immunome has a consensus target price of $34.25, suggesting a potential upside of 63.88%. Given Annexon's higher possible upside, equities research analysts clearly believe Annexon is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Annexon has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Immunome has a beta of 2.55, indicating that its stock price is 155% more volatile than the broader market.

In the previous week, Annexon and Annexon both had 8 articles in the media. Annexon's average media sentiment score of 0.83 beat Immunome's score of 0.64 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	1 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

44.6% of Immunome shares are held by institutional investors. 10.3% of Annexon shares are held by insiders. Comparatively, 7.2% of Immunome shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Annexon has higher earnings, but lower revenue than Immunome. Immunome is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Immunome	$6.94M	342.05	-$212.39M	-$2.53	N/A

Summary

Immunome beats Annexon on 7 of the 13 factors compared between the two stocks.

How does Annexon compare to CareDx?

CareDx (NASDAQ:CDNA) and Annexon (NASDAQ:ANNX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

In the previous week, Annexon had 4 more articles in the media than CareDx. MarketBeat recorded 8 mentions for Annexon and 4 mentions for CareDx. Annexon's average media sentiment score of 0.83 beat CareDx's score of 0.52 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CareDx has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market. Comparatively, Annexon has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

CareDx presently has a consensus target price of $54.00, indicating a potential downside of 19.58%. Annexon has a consensus target price of $15.29, indicating a potential upside of 264.81%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

CareDx has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	9.15	-$21.35M	$2.07	32.44
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

CareDx has a net margin of 24.23% compared to Annexon's net margin of 0.00%. CareDx's return on equity of 2.87% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	24.23%	2.87%	2.17%
Annexon	N/A	-106.15%	-79.82%

Summary

CareDx beats Annexon on 10 of the 14 factors compared between the two stocks.

How does Annexon compare to Gemini Therapeutics?

Annexon (NASDAQ:ANNX) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Annexon presently has a consensus price target of $15.29, suggesting a potential upside of 264.81%. Given Annexon's stronger consensus rating and higher probable upside, research analysts plainly believe Annexon is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Annexon had 8 more articles in the media than Gemini Therapeutics. MarketBeat recorded 8 mentions for Annexon and 0 mentions for Gemini Therapeutics. Annexon's average media sentiment score of 0.83 beat Gemini Therapeutics' score of 0.00 indicating that Annexon is being referred to more favorably in the media.

Company	Overall Sentiment
Annexon	Positive
Gemini Therapeutics	Neutral

Annexon has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics' return on equity of -38.78% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Gemini Therapeutics	N/A	-38.78%	-35.88%

75.4% of Gemini Therapeutics shares are owned by institutional investors. 10.3% of Annexon shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Annexon beats Gemini Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Annexon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANNX vs. The Competition

Export

Metric	Annexon	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$794.34M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-3.61	13.06	275.66	26.04
Price / Sales	N/A	1,292.11	608.92	91.72
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	2.95	16.63	10.93	6.31
Net Income	-$206.69M	-$22.71M	$3.51B	$362.16M
7 Day Performance	15.11%	-2.99%	-2.00%	-1.66%
1 Month Performance	-13.96%	-10.81%	-6.19%	-4.68%
1 Year Performance	31.35%	19.19%	8.03%	1.57%

Annexon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANNX Annexon	3.5959 of 5 stars	$4.19 +1.7%	$15.29 +264.8%	+31.3%	$794.34M	N/A	N/A	92	Analyst Forecast
QURE uniQure	2.6702 of 5 stars	$38.32 -10.4%	$65.00 +69.6%	-57.3%	$3.14B	$16.10M	N/A	221	Analyst Forecast Options Volume High Trading Volume
ZLAB Zai Lab	1.8299 of 5 stars	$25.28 -4.4%	$37.25 +47.3%	-27.9%	$3.01B	$460.16M	N/A	1,784
IMNM Immunome	2.638 of 5 stars	$22.34 -7.8%	$35.18 +57.5%	+68.8%	$2.92B	$6.94M	N/A	177	News Coverage Analyst Forecast Gap Up High Trading Volume
CDNA CareDx	2.3131 of 5 stars	$61.37 +13.0%	$54.00 -12.0%	+342.1%	$2.92B	$379.80M	29.65	765	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANNX) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annexon (ANNX) Competitors